Suria ABDUL Abdul Aziz

Dr. Suria ABDUL Abdul Aziz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in Biology
Verified
Journal Article
Open access
PDF file
Li Ting KeeLi Ting Kee
Li Ting Kee
YLYi Ting Lee
Yi Ting Lee
CNChiew Yong Ng
Chiew Yong Ng
MHMuhammad Najib Fathi Hassan
Muhammad Najib Fathi Hassan
MNMin Hwei Ng
Min Hwei Ng
Jia Xian LawJia Xian Law
Jia Xian Law
Human platelet lysate (hPL) has high levels of fibrinogen and coagulation factors, which can lead to gel and precipitate formation during storage and cell culture. Heparin derived from animals is commonly added to minimize these risks, but cannot completely eliminate them. Thus, this study proposes an alternative method to prepare fibrinogen-depleted hPL (Fd-hPL) that supports heparin-free expansion of mesenchymal stem cells (MSCs). hPL was added to heparin to prepare heparin-hPL (H-hPL), whilst Fd-hPL was prepared by adding calcium salt to hPL to remove the fibrin clot. The concentrations of calcium, fibrinogen, and growth factors in H-hPL and Fd-hPL were compared. The effects of H-hPL and Fd-hPL on umbilical cord-derived MSCs (UC-MSCs) were assessed. The results showed that Fd-hPL possessed a significantly higher calcium concentration and a lower fibrinogen level than H-hPL. The concentrations of BDNF, TGF-β1, and PDGF-BB showed no significant difference between H-hPL and Fd-hPL, but Fd-hPL had a lower VEGF concentration. Fd-hPL retained the characteristics of UC-MSCs, as it did not affect the cell viability, proliferation, multilineage differentiation potential, or surface marker expression. In conclusion, Fd-hPL effectively supported the in vitro expansion of MSCs without compromising their characteristics, positioning it as a potential substitute for FBS in MSC culture.

1 June 2022 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
RHRoszymah Hamzah
Roszymah Hamzah
DYDr Nurasyikin Yusof
Dr Nurasyikin Yusof
NTNor Rafeah Tumian
Nor Rafeah Tumian
SASuria ABDUL Abdul Aziz
Suria ABDUL Abdul Aziz
NBNur Syahida Mohammad Basri
Nur Syahida Mohammad Basri
SJSiti Afiqah Muhamad Jamil
Siti Afiqah Muhamad Jamil
Background: Immune thrombocytopenia (ITP) is well characterized in Western, European and other Asia-Pacific countries. Nevertheless, the clinical epidemiology, treatment pattern and disease outcome of ITP in Malaysia are still limited and not well known. Objective: This study aimed to describe the clinical epidemiology, treatment outcome and mortality of ITP patients in haematology tertiary multicentre in Malaysia. Methods: Clinical and laboratory data of newly diagnosed adults with ITP by a platelet count < 100 × 109/L from January 2010 to December 2020 were identified and analyzed. Results: Out of 500 incident ITP, 71.8% were females with a striking age preponderance of both genders among those aged 18– 29 years. The median age was 36 years. The median platelet count was 17.5 × 109/L, 23.0% had a secondary ITP, 34.6% had a Charlson’s score ≥ 1, 53.0% had bleeding symptoms including 2.2% intracranial bleedings (ICB). Helicobacter pylori screening was performed in < 5% of cases. Persistency and chronicity rates were 13.6% and 41.8%, respectively. Most (80.6%) were treated at diagnosis onset and 31.2% needed second-line treatment. Throughout the course of ITP, 11.0% of patients died; 3.0% and 8.0% with bleeding and non-bleeding related ITP. Conclusion: This study confirms the epidemiology of ITP is comparable with worldwide studies. Our incidence is high in the female, Malay ethnicity, primary ITP and events of cutaneous bleeding at ITP onset with 18– 29 years predominance age group for both genders. The frequency of persistent and chronic ITP is inconsistent with published literature. Corticosteroids and immunotherapies are the most prescribed first-line and second-line pharmacological treatments. Thrombopoietin receptor agonist medications (TPO-RAs) usage is restricted and splenectomy is uncommon. Our mortality rate is similar but ITP related bleeding death is fourth-fold lower than previous studies. Mortality risks of our ITP patients include age ≥ 60 years, male, severe bleeding at presentation, CCI≥ 1 and secondary ITP.

16 February 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
MKMohamad Raihan Bin Kamaruddin
Mohamad Raihan Bin Kamaruddin
BBBahiratuz Zulfa Baharuddin
Bahiratuz Zulfa Baharuddin
NMNahgeshwarie Ratha Manaalan
Nahgeshwarie Ratha Manaalan
WLWong Yi Lyn
Wong Yi Lyn
MHMuhammad Najib Fathi Hassan
Muhammad Najib Fathi Hassan
Jia Xian LawJia Xian Law
Jia Xian Law
Background and aims: Enhanced cell proliferation is crucial for reducing production time and cost in cell therapy, and human platelet lysate (HPL) is often used to boost cell proliferation due to its favorable safety profile. Understanding the roles of different HPL components and their effects on cell culture can lead to more informed choices in medium formulation, which in turn can influence cell behavior and outcomes. Therefore, this study aimed to investigate the effects of two types of HPL, i.e., heparin-supplemented HPL (He-HPL) and fibrinogen-depleted HPL without heparin (Fd-HPL), on human osteoblasts. Materials and Methods: He-HPL and Fd-HPL were prepared from expired platelet concentrates. The presence of growth factors, i.e., brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF), and cytokines, i.e., interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), in HPL was evaluated. Human fetal osteoblast (hFOB) cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with either He-HPL or Fd-HPL. The cell morphology, viability, calcium deposition, and expression of osteogenic genes were assessed. Results: Comparable levels of BDNF (p > 0.05), VEGF (p > 0.05), and IL-6 (p > 0.05) were detected in both types of HPL, whereas He-HPL exhibited significantly higher levels of TNF-α (p < 0.05). However, there were no notable differences in cell morphology, viability, population doubling time, or total cell yield between the two HPL types. Similarly, no differences were observed in the mineralization of cells treated with He-HPL compared to Fd-HPL. Nonetheless, hFOB cells cultured with He-HPL demonstrated significantly higher expression of osteogenic markers Runx2 and ALP (p < 0.05) compared to those cultured with Fd-HPL. Conclusions: He-HPL and Fd-HPL demonstrate comparable performance in promoting osteoblast proliferation and mineralization, making both usable for bone tissue engineering. However, He-HPL might have a slight edge as it enhances osteogenic gene expression.

27 March 2024 in Bangladesh Journal of Medical Science
Verified
Journal Article
Open access
PDF file
RYRabeya Yousuf
Rabeya Yousuf
NYNurasyikin Yusof
Nurasyikin Yusof
NSNur Afifah Suhemi
Nur Afifah Suhemi
NTNor Fadzliana Abdullah Thalith
Nor Fadzliana Abdullah Thalith
SASuria ABDUL Abdul Aziz
Suria ABDUL Abdul Aziz
Weaker subgroups have the potential to cause problems in the immunohaematological testing in the blood banks. We report here a case of rare weaker subgroup A, detected during the usual ABO grouping. A 49-year-old lady exhibited a discrepancy in the forward and reverse groupings. In forward-grouping, there was a mixedfield reaction with anti-A and anti-A,B while there was no reaction with anti-B. The reverse grouping showed no reaction with the A1 and A2 cells, but the reaction with B-cell was 4+. Further tests were performed and revealed a weaker subgroup of A. It is crucial to properly investigate and resolve any discrepancy in ABO grouping before commencing transfusion to avoid any wrong blood transfusion. This case report may assist others in resolving the ABO blood group discrepancies. Bangladesh Journal of Medical Science Vol. 23 No. 02 April’24 Page : 546-550